drugset / Trial / NCT05946876
A Phase 1 Study of XH-S003 in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a phase 1, randomised, first-in-human, double-blinded, placebo-controlled, SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) study to assess the PK, safety, and tolerability of XH-S003 in healthy volunteers. In addition, this study evaluates the effects of food on XH-S003 under a two-period, cross-over study setting.
Timeline
- Start
- 2023-08-24
- Primary completion
- 2024-07-11
- Completion
- 2024-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XH-S003 | Unknown | 25 mg | Oral |
| Subject | XH-S003 | Unknown | 50 mg | Oral |
| Subject | XH-S003 | Unknown | 100 mg | Oral |
| Subject | XH-S003 | Unknown | 200 mg | Oral |
| Subject | XH-S003 | Unknown | 400 mg | Oral |
Indications
No indication recorded.